→ Trevi Therapeutics in New Haven, CT has raised a $50.5 million C round. The biotech has been pushing a drug called Nalbuphine ER through mid-stage trials, gathering data on its ability to reduce itching caused by a range of conditions. And former Sanofi-Genzyme chief David Meeker is taking the chairman’s post as part of the financing. New Enterprise Associates led the financing round, which included new investors Lundbeckfonden Ventures, Omega Funds and Aperture Venture Partners, along with TPG Biotech.
→ Spark Therapeutics’ new gene therapy for RPE65 mutation-associated retinal dystrophy has been designated as a rare pediatric disease drug. The designation carries with it the right to a priority review voucher, if an approval comes through. Spark $ONCE has been angling for the first US gene therapy approval and the drug is currently under review.
→ Theravance and Mylan completed a 12-month safety study on revefenacin (TD-4208), their once-daily, nebulized LAMA for COPD. The partners say the study went well and that they are still on track for wrapping their NDA in the fourth quarter.
→ GSK has sold off another asset. Emergent BioSolutions has acquired its anthrax drug Raxibacumab for up to $96 million.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription